Lamotrigine in the treatment of bipolar disorder

Charles L. Bowden, Nancy U. Karren

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Lamotrigine has undergone a remarkable series of systematic studies since 1994 that now establish it as an efficacious, well-tolerated treatment in bipolar disorder. Its efficacy principally addresses both acute and maintenance phase benefits on depressive symptomatology. These benefits have been demonstrated in placebo-controlled studies, rapid cycling patients, bipolar I and II patients and monotherapy as well as in combination therapy, although this has been less well studied. The drug is exceptionally well-tolerated in long-term treatment, although initial dosing requires gradual dosage escalation to avoid the risk of inducing serious rashes with features within the spectrum of Stevens-Johnson syndrome. Administration with valproate requires a slower dosage titration, whereas, as with many drugs, administration with carbamazepine requires a more rapid dosage increase. In contrast to marketed antidepressants, lamotrigine appears not to induce manic or hypomanic episodes, nor to increase cycling frequency. This combination of properties makes it a first-choice treatment for acute bipolar depression and continuation treatment, especially, but not limited to, prophylaxis against recurrent depression and depressive symptoms. Lamotrigine appears not to have acute antimanic properties. A small number of studies suggest a broader spectrum of efficacy, including in some axis I disorders that are comorbidly associated with bipolar disorder.

Original languageEnglish (US)
Pages (from-to)1513-1519
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume3
Issue number10
DOIs
StatePublished - Oct 1 2002

Fingerprint

Bipolar Disorder
Antimanic Agents
Depression
Therapeutics
Stevens-Johnson Syndrome
Carbamazepine
Valproic Acid
Exanthema
Pharmaceutical Preparations
Antidepressive Agents
Placebos
Maintenance
lamotrigine

Keywords

  • Bipolar
  • Depression
  • Lamotrigine
  • Manic-depressive
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Lamotrigine in the treatment of bipolar disorder. / Bowden, Charles L.; Karren, Nancy U.

In: Expert Opinion on Pharmacotherapy, Vol. 3, No. 10, 01.10.2002, p. 1513-1519.

Research output: Contribution to journalArticle

Bowden, Charles L. ; Karren, Nancy U. / Lamotrigine in the treatment of bipolar disorder. In: Expert Opinion on Pharmacotherapy. 2002 ; Vol. 3, No. 10. pp. 1513-1519.
@article{e5edeee1ab584ac090cf9dcd3374712c,
title = "Lamotrigine in the treatment of bipolar disorder",
abstract = "Lamotrigine has undergone a remarkable series of systematic studies since 1994 that now establish it as an efficacious, well-tolerated treatment in bipolar disorder. Its efficacy principally addresses both acute and maintenance phase benefits on depressive symptomatology. These benefits have been demonstrated in placebo-controlled studies, rapid cycling patients, bipolar I and II patients and monotherapy as well as in combination therapy, although this has been less well studied. The drug is exceptionally well-tolerated in long-term treatment, although initial dosing requires gradual dosage escalation to avoid the risk of inducing serious rashes with features within the spectrum of Stevens-Johnson syndrome. Administration with valproate requires a slower dosage titration, whereas, as with many drugs, administration with carbamazepine requires a more rapid dosage increase. In contrast to marketed antidepressants, lamotrigine appears not to induce manic or hypomanic episodes, nor to increase cycling frequency. This combination of properties makes it a first-choice treatment for acute bipolar depression and continuation treatment, especially, but not limited to, prophylaxis against recurrent depression and depressive symptoms. Lamotrigine appears not to have acute antimanic properties. A small number of studies suggest a broader spectrum of efficacy, including in some axis I disorders that are comorbidly associated with bipolar disorder.",
keywords = "Bipolar, Depression, Lamotrigine, Manic-depressive, Treatment",
author = "Bowden, {Charles L.} and Karren, {Nancy U.}",
year = "2002",
month = "10",
day = "1",
doi = "10.1517/14656566.3.10.1513",
language = "English (US)",
volume = "3",
pages = "1513--1519",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Lamotrigine in the treatment of bipolar disorder

AU - Bowden, Charles L.

AU - Karren, Nancy U.

PY - 2002/10/1

Y1 - 2002/10/1

N2 - Lamotrigine has undergone a remarkable series of systematic studies since 1994 that now establish it as an efficacious, well-tolerated treatment in bipolar disorder. Its efficacy principally addresses both acute and maintenance phase benefits on depressive symptomatology. These benefits have been demonstrated in placebo-controlled studies, rapid cycling patients, bipolar I and II patients and monotherapy as well as in combination therapy, although this has been less well studied. The drug is exceptionally well-tolerated in long-term treatment, although initial dosing requires gradual dosage escalation to avoid the risk of inducing serious rashes with features within the spectrum of Stevens-Johnson syndrome. Administration with valproate requires a slower dosage titration, whereas, as with many drugs, administration with carbamazepine requires a more rapid dosage increase. In contrast to marketed antidepressants, lamotrigine appears not to induce manic or hypomanic episodes, nor to increase cycling frequency. This combination of properties makes it a first-choice treatment for acute bipolar depression and continuation treatment, especially, but not limited to, prophylaxis against recurrent depression and depressive symptoms. Lamotrigine appears not to have acute antimanic properties. A small number of studies suggest a broader spectrum of efficacy, including in some axis I disorders that are comorbidly associated with bipolar disorder.

AB - Lamotrigine has undergone a remarkable series of systematic studies since 1994 that now establish it as an efficacious, well-tolerated treatment in bipolar disorder. Its efficacy principally addresses both acute and maintenance phase benefits on depressive symptomatology. These benefits have been demonstrated in placebo-controlled studies, rapid cycling patients, bipolar I and II patients and monotherapy as well as in combination therapy, although this has been less well studied. The drug is exceptionally well-tolerated in long-term treatment, although initial dosing requires gradual dosage escalation to avoid the risk of inducing serious rashes with features within the spectrum of Stevens-Johnson syndrome. Administration with valproate requires a slower dosage titration, whereas, as with many drugs, administration with carbamazepine requires a more rapid dosage increase. In contrast to marketed antidepressants, lamotrigine appears not to induce manic or hypomanic episodes, nor to increase cycling frequency. This combination of properties makes it a first-choice treatment for acute bipolar depression and continuation treatment, especially, but not limited to, prophylaxis against recurrent depression and depressive symptoms. Lamotrigine appears not to have acute antimanic properties. A small number of studies suggest a broader spectrum of efficacy, including in some axis I disorders that are comorbidly associated with bipolar disorder.

KW - Bipolar

KW - Depression

KW - Lamotrigine

KW - Manic-depressive

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0036796487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036796487&partnerID=8YFLogxK

U2 - 10.1517/14656566.3.10.1513

DO - 10.1517/14656566.3.10.1513

M3 - Article

VL - 3

SP - 1513

EP - 1519

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 10

ER -